Clinical trials: B-cell Malignancies
Acute Lymphoblastic Leukemia
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
To evaluate the safety and tolerability of Human CD19-CD22 Targeted T Cells Injection for the treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
- Trial name
- NCT05223686
- Testing
- Human CD19-CD22 Targeted T Cells Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Lymphoma, Non-Hodgkin
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- TRANSFORM (NCT03575351)
- Testing
- Standard of Care, JCAR017
- Where
- 54 sites in United States, Belgium and 10 more
- Volunteers
- 184 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2).
- Trial name
- CARTITUDE-1 (NCT03548207)
- Testing
- JNJ-68284528
- Where
- 21 sites in United States, Japan
- Volunteers
- 126 people
- Sponsor
- Janssen Research & Development, LLC
Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL)
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor…
- Trial name
- NCT06392763
- Where
- France
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Large B Cell Lymphoma, LBCL
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with…
- Conditions
- Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma
- Trial name
- NCT07875413
- Testing
- Prizloncabtagene Autoleucel
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- AbelZeta Inc.
Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
According to health authorities guidances (FDA 2006, EMA(European Medicines Agency) 2009) for gene therapy clinical trials, observing subjects for delayed adverse events for 15 years is recommended.
- Conditions
- Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma Grade 3A
- Trial name
- NCT05377307
- Testing
- Pell's lentiviral-based gene-edited immune cell therapy
- Where
- 5 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- Pell Bio-Med Technology Co., Ltd.
Diffuse Large B-cell Lymphoma
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30…
- Trial name
- NCT03145064
- Testing
- Zanubrutinib
- Where
- 11 sites in China
- Volunteers
- 41 people
- Sponsor
- BeiGene
Diffuse Large B-cell Lymphoma (DLBCL)
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)
A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs…
- Trial name
- NCT05366257
- Testing
- CAR-T, Allo-HSCT cohort
- Where
- United States
- Volunteers
- 160,602 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
The purpose of the study is to evaluate the effects of increasing doses of CNF1010 on pharmacodynamic markers and hematological response.
- Trial name
- NCT00319930
- Testing
- CNF1010 (17-AAG)
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Biogen
Chronic Lymphocytic Leukemia
Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia
A Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia A retrospective, multi-centre, observational study to…
- Trial name
- CREEK (NCT04964908)
- Where
- 52 sites in Argentina, Brazil and 15 more
- Volunteers
- 1,088 people
- Sponsor
- AstraZeneca
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Lymphoma, B-Cell
Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)
To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in patients with B-Cell Non-Hodgkin's Lymphoma (NHL).
- Trial name
- NCT00717925
- Testing
- Inotuzumab Ozogamicin (CMC-544)
- Volunteers
- 13 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Chronic Lymphocytic Leukemia
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to evaluate the safety and efficacy of NOX A12 in combination with a background therapy of bendamustine and rituximab (BR) chemotherapy in previously treated patients with chronic lymphocytic leukemia…
- Trial name
- NCT01486797
- Testing
- NOX-A12
- Where
- 17 sites in Austria, Belgium and 2 more
- Volunteers
- 28 people
- Sponsor
- TME Pharma AG
Follicular Lymphoma, Chronic Lymphocytic Leukemia
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
This study will evaluate the safety and tolerability of GS-9901 monotherapy in adults with follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL).
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT02258555
- Testing
- GS-9901
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gilead Sciences
Lymphoma. Non-Hodgkin
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
The purpose of this study is to determine whether Nivolumab is effective in the treatment of DLBCL in patients that have failed or are ineligible for ASCT
- Trial name
- NCT02038933
- Testing
- Nivolumab
- Where
- 46 sites in United States, Australia and 10 more
- Volunteers
- 121 people
- Sponsor
- Bristol-Myers Squibb
Chronic Lymphocytic Leukaemia, Patients Resistant to a Purine Analogous
R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia
Since there is no standard rescue therapy for refractory CLL or relapsed to the purine analogous, our target is to carry out a rescue therapy combining several chemotherapy agents (CHOP) adding the synergistic effect of Rituximab…
- Conditions
- Chronic Lymphocytic Leukaemia, Patients Resistant to a Purine Analogous, Patients Relapsed With Purines Therapy
- Trial name
- R-CHOP (NCT00504491)
- Testing
- Rituximab-CHOP-Alemtuzumab
- Where
- 32 sites in Spain
- Sponsor
- CABYC
B-cell Malignancies, Colorectal Cancer (CRC)
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
This is a Phase 1/2, open label study. Phase 1 consists of 2 parts. Part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors…
- Conditions
- B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer
- Trial name
- NCT02327078
- Testing
- Nivolumab, Epacadostat, Chemotherapy
- Where
- 24 sites in United States, United Kingdom
- Volunteers
- 307 people
- Sponsor
- Incyte Corporation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia
This is a single-arm, multi-center, open-label, Phase 2 study to determine the efficacy and safety of JCAR015 in adult subjects with B-cell ALL.
- Trial name
- ORBIT (NCT02973191)
- Testing
- JCAR015
- Where
- 18 sites in Belgium, France and 5 more
- Sponsor
- Celgene
Chronic Lymphocytic Leukemia
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
The main objective of this study is to determine the progression free survival of umbralisib in participants who were intolerant to prior BTK (Bruton Tyrosine Kinase) inhibitors (ibrutinib, ACP-196, other) or prior PI3K-delta…
- Trial name
- NCT02742090
- Testing
- Umbralisib
- Where
- 15 sites in United States
- Volunteers
- 51 people
- Sponsor
- TG Therapeutics, Inc.
Lymphoma, Mantle-Cell
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by…
- Trial name
- BRUIN-MCL-321 (NCT04662255)
- Testing
- Pirtobrutinib, Ibrutinib, Acalabrutinib
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 500 people
- Sponsor
- Loxo Oncology, Inc.